2024
Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study
Gleason C, Dowling N, Kara F, James T, Salazar H, Simo C, Harman S, Manson J, Hammers D, Naftolin F, Pal L, Miller V, Cedars M, Lobo R, Malek-Ahmadi M, Kantarci K. Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. PLOS Medicine 2024, 21: e1004435. PMID: 39570992, PMCID: PMC11581397, DOI: 10.1371/journal.pmed.1004435.Peer-Reviewed Original ResearchConceptsOral conjugated equine estrogenLatent growth modelingLong-term cognitive effectsCognitive factor scoresCognitive benefitsCognitive performanceFactor scoresBaseline cognitionFollow-upClinical trialsEarly postmenopauseIn-person research visitsYears of follow-upRandomized to placeboMenopausal hormone therapyGlobal cognitive scoreNeuroimaging effectsCognitive measuresCognitive harmLongitudinal cohort studyCognitive changesCognitive slopesCognitive dataTest batteryCognitive function
2023
Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial
Kantarci K, Tosakulwong N, Lesnick T, Kara F, Kendall-Thomas J, Kapoor E, Fields J, James T, Lobo R, Manson J, Pal L, Hammers D, Malek-Ahmadi M, Cedars M, Naftolin F, Santoro N, Miller V, Harman S, Dowling N, Gleason C. Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial. Menopause The Journal Of The North American Menopause Society 2023, 31: 10-17. PMID: 37989141, PMCID: PMC10756493, DOI: 10.1097/gme.0000000000002278.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyOral conjugated equine estrogenConjugated equine estrogensBetter cardiovascular healthHormone therapyEquine estrogensInsulin resistanceMenopausal womenCardiovascular healthClinical trialsHormone therapy trialsPerson clinic visitsDiastolic blood pressureHomeostasis model assessmentSelf-reported diabetesYears of onsetMultisite clinical trialLevels of glucoseMicronized progesteroneDiabetes medicationsStudy of participantsCardiometabolic effectsCardiometabolic outcomesClinic visitsBlood pressure
2022
Follicle-stimulating hormone (and luteinizing hormone) in ovarian stimulation: Does the dose matter for cycle success?
Kuokkanen S, Pal L. Follicle-stimulating hormone (and luteinizing hormone) in ovarian stimulation: Does the dose matter for cycle success? Fertility And Sterility 2022, 119: 166-169. PMID: 36529184, DOI: 10.1016/j.fertnstert.2022.12.019.Peer-Reviewed Original ResearchAssociations between pituitary-ovarian hormones and cognition in recently menopausal women independent of type of hormone therapy
Kling J, Dowling N, Bimonte-Nelson H, Gleason C, Kantarci K, Stonnington C, Harman S, Naftolin F, Pal L, Cedars M, Manson J, James T, Brinton E, Miller V. Associations between pituitary-ovarian hormones and cognition in recently menopausal women independent of type of hormone therapy. Maturitas 2022, 167: 113-122. PMID: 36395695, PMCID: PMC10077876, DOI: 10.1016/j.maturitas.2022.10.002.Peer-Reviewed Original ResearchConceptsComplex attention tasksLatent growth curve modelsPoor cognitive performancePoorer global cognitionGrowth curve modelsAuditory attentionAttention taskCognitive factorsMental flexibilityVisual attentionExecutive functionCognitive domainsCognitive performanceCognitive trajectoriesGlobal cognitionPituitary-ovarian hormonesHormone therapyBaseline cognitionCognitionHormone levelsNeuropsychological testingMonth 18Menopausal womenEstrone levelsMonth 48
2008
Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization
Pal L, Jindal S, Witt BR, Santoro N. Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization. Fertility And Sterility 2008, 89: 1694-1701. PMID: 18440515, PMCID: PMC2601677, DOI: 10.1016/j.fertnstert.2007.05.055.Peer-Reviewed Original ResearchConceptsNondonor IVF cyclesClinical pregnancyCycle cancellationLive birthsGonadotropin useIVF cyclesSpontaneous miscarriageOvarian reserve statusOvarian hyperstimulation resultsHigh gonadotropinsOvarian stimulationFertilization cyclesIVF outcomesOocyte yieldWorse prognosisRetrospective studyIVF centerImproved outcomesAggressive approachMAIN OUTCOMEPregnancyIVFHigher likelihoodBirthOutcomes
1997
Outcome of IVF in DES-Exposed Daughters: Experience in the 90s
Pal L, Shifren J, Isaacson K, Chang Y, Marean M, Leykin L, Toth T. Outcome of IVF in DES-Exposed Daughters: Experience in the 90s. Journal Of Assisted Reproduction And Genetics 1997, 14: 513-517. PMID: 9401869, PMCID: PMC3454843, DOI: 10.1023/a:1021175326230.Peer-Reviewed Original ResearchConceptsMassachusetts General HospitalOngoing pregnancy rateOutcome of IVFIVF cyclesInfertile womenUtero exposurePregnancy rateAcademic IVF programDay 3 levelsOutcome of ARTSelf-reported historyQuality of embryosOvarian hyperstimulationUtero DiethylstilbestrolControl patientsIdiopathic infertilitySerum estradiolImplantation rateInfertile patientsIVF programGeneral HospitalIVF unitEmbryo transferPatientsLow implantation